Novo Nordisk stock pops on Phase 1 data for new weight loss drug amycretin
Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 products, by mimicking a hormone in the body that provides a satiated feeling and curbs hunger, but adds a different hormone in the pancreas.
Novo Nordisk is slammed by U.K. trade group for not disclosing payments to health and patient groups
Novo Nordisk was slammed by a U.K. trade group for not disclosing payments to health and patient groups, according to a draft ...
Good news about an experimental weight-loss shot sent shares in Ozempic maker Novo Nordisk soaring, making it once again Europe's most-valuable listed company. A pullback in the Danish drug maker's ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/17.OJtTHmzH.js ...
Twilio stock is one of the best-performing stocks Friday after the tech company revealed its three-year profit forecast at an ...
Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an ...
Follow along for live updates on stocks, bonds and other markets, including the Dow Jones Industrial Average, S&P 500 and Nasdaq Composite.
U.S. stocks are hanging near their all-time high on Friday as they head for the close of a second straight winning week.
Danish healthcare company Novo Nordisk A/S (NVO) announced topline results from a phase 1b/2a clinical trial with amycretin, a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback